NL-OMON37797尚未招募4 期
Effects of vernakalant and flecainide on atrial contractility in patients with atrial fibrillation - Vernakalant versus flecainide: atrial contractility
Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- patients presenting with paroxysmal or persistent AF;- eligible for treatment with flecainide or vernakalant infusion to restore sinus rhythm;- receiving adequate anticoagulant therapy (or having an episode of AF lasting < 24 hours)
排除标准
- •- atrial flutter;- contra-indications for receiving flecainide or vernakalant infusion according to MUMC+ protocol (unstable hemodynamic condition, LVEF < 40%, inadequate potassium levels, acute ischaemia, sinus node dysfunction);- age < 18 years
研究者
相似试验
进行中（未招募）
不适用
Effects of vernakalant and flecainide on atrial contractility in patients with AFPatients with paroxysmal or persistent atrial fibrillation (AF) reporting at the first heart aid.EUCTR2012-001898-90-NLMaastricht University Medical Center
Unknown
4 期
Vernakalant Versus Flecainide: Atrial ContractilityAtrial FibrillationNCT01646281Maastricht University Medical Center70
尚未招募
不适用
A clinical trial to study the effects Flecainide on HV interval in patients with symptomatic Bifascicular blockCTRI/2020/12/029543King George Medical University
招募中
3 期
Effect of Colchicine on the Prevention of Atrial Fibrillation after Coronary Artery Bypass Grafting Surgery(CABG)Atrial Fibrillation.?????? ??? ??? ? ????I00-I99IRCT20220515054855N1Mazandaran University of Medical Sciences230
招募中
不适用
In-vivo Bioequivalence Test of Flecainide acetate tablets with brand drug (TAMBOCOR® 100 mg FC Tab, MEDA Pharmaceuticals LLC, USA)IRCT20200105046010N48Arena Hayat Danesh Pharmaceutical Company24